Two biosimilars developed under the Teva - Alvotech partnership have been granted FDA approval with interchangeability, including SELARSDI. In February 2024, the FDA approved SIMLANDI® ...

The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

When Roy Bradley was told he had cancer in his lungs and liver, his first thought was he couldn't face chemotherapy and ...

Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Kyprolis ...

Dr. Hall, who previously held leadership positions at multiple biotech companies ... of therapeutics including the monoclonal antibodies HUMIRA (adalimumab) and PROLIA (denosumab).

AbbVie has already paid the Belgian biotech $175 million to ... is possible,” he added. Anti-drug antibodies were produced at similar levels to Humira, but with no impact on safety and ...

Patents for RANKL antibodies (including sequences ... However, sales of Amjevita/Amgevita, a biosimilar version of AbbVie’s Humira, are likely to have increased. Amgen launched the biosimilar ...

After surging approval outputs in 2023, including nine biosimilars of AbbVie’s immunology giant Humira, the FDA cleared 19 follow ... Famously, in 1997, rituximab became the first-ever approved ...

UK biotech Bicycle Therapeutics has raised £ ... These are designed to have the affinity and selective pharmacology of antibodies, the distribution kinetics of small molecules, (allowing rapid ...